Rationale and objectives: Diffusion-weighted imaging (DWI) is central to prostate magnetic resonance imaging (MRI) but lengthens examinations. We evaluated whether an artificial intelligence (AI)-accelerated, reduced-field-of-view diffusion sequence (AI-DWI) could shorten scan time without sacrificing perceived diagnostic image quality, and how it affects quantitative diffusion metrics.
Materials and methods: This prospective, single-center study of diagnostic accuracy enrolled consecutive men with elevated prostate-specific-antigen levels between March and May 2025. The index AI-DWI sequence was compared against the standard conventional DWI sequence (c-DWI) for each patient. Three radiologists scored subjective image quality. Quantitative analysis involved comparing mean apparent diffusion coefficient (ADC) and seven additional texture features. Wilcoxon signed-rank tests assessed ordinal scores, and paired t-tests were used for quantitative metrics.
Results: 62 men (mean age, 68.7 years ± 9) were evaluated. The AI-DWI sequence demonstrated a significantly shorter acquisition time compared to c-DWI (3 min 59 s vs. 4 min 21 s; p<0.01). There was no significant difference in subjective scores for overall image quality, lesion conspicuity, artifacts, or anatomic differentiability (p>0.05 for all). AI-DWI yielded significantly lower mean ADC values (975.92±174.57 vs. 1013.21±189.34; adj. p<0.01) and maximum ADC values (adj. p<0.01). No significant differences were found for standard deviation, coefficient of variation, entropy, kurtosis, minimum, or skewness (adj. p>0.05).
Conclusion: The AI-DWI sequence allows for reduced acquisition time while preserving subjective image quality compared to the c-DWI. Quantitatively, it yields lower mean and maximum ADC values, while showing no significant differences in the rest of the quantitative metrics relative to the conventional sequence.
Background: Evidence regarding the long-term outcomes of patients with mild large vessel occlusion (LVO) stroke remains limited. This study aimed to compare 12-month outcomes between acute ischemic stroke (AIS) patients treated with endovascular therapy (EVT) versus best medical management (BMM).
Methods: A multicenter, retrospective study across three centers was conducted, including AIS patients with LVO and National Institutes of Health Stroke Scale score (NIHSS) <6 between January 2019 and December 2023. Patients were categorized into EVT or BMM groups according to initial treatment strategy. The primary outcome was functional independence (modified Rankin Scale score of 0-2) at 12 months. Inverse probability of treatment weighting (IPTW) based on propensity scores was used to adjust for potential confounders.
Results: A total of 976 patients with LVO were screened, and 285 with NIHSS <6 were enrolled. After IPTW adjustment (195 EVT vs. 201 BMM), functional independence was achieved in 78.5% of EVT and 74.1% of BMM patients (adjusted odds ratio [aOR] 1.25, 95% confidence interval [CI] 0.70-2.20) at 12 months. Hemorrhagic transformation was more frequent in the EVT group (13.3% vs. 5.5%; aOR 2.63, 95% CI 1.20-5.85), whereas symptomatic intracranial hemorrhage rates were similar between groups. Notably, stroke recurrence within 12 months was significantly lower in the EVT group compared to the BMM group (4.6% vs. 12.9%; aOR 0.33, 95% CI 0.15-0.70).
Conclusion: In patients with mild LVO, no statistically significant difference in long-term functional outcomes was observed between EVT and BMM, although EVT was associated with a lower risk of stroke recurrence.

